Valiant Laboratories Ltd

Valiant Laboratories Ltd announced that India Ratings and Research (Ind-Ra) has issued a credit rating to the company’s bank loan facilities, assigning an IND BBB rating to the INR 560 million bank loan facilities, along with a Stable Outlook and an IND A2 rating; the detailed rating rationale and instrument-wise rating actions can be accessed at https://www.indiaratings.co.in/pressrelease/85089, and this intimation has also been uploaded on the company’s website at www.valiantlabs.in.

Valiant Laboratories Limited announced the re-appointment of Mr. Santosh Vora as Managing Director for five years, effective February 6, 2027, and Mrs. Sonal Vira as an Independent Director for a second five-year term, also effective February 16, 2027, both subject to shareholder approval. The company also approved the continuation of Mr. Shantilal Vora as a Non-Executive Non-Independent Director and plans to shift its registered office to Plot No. L-13, L -28, L -28(Pt), L -29 & L -30, MIDC Tarapur, Boisar, Palghar, Maharashtra – 401506, and open a new corporate office in Mumbai. Additionally, Valiant Laboratories intends to invest up to Rs 60 crore in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited, to meet working capital needs.

Valiant Laboratories Limited announced the re-appointment of Mr. Santosh Vora as Managing Director for five years, effective February 6, 2027, and Mrs. Sonal Vira as an Independent Director for a second five-year term, also effective February 16, 2027, both subject to shareholder approval. The company also approved the continuation of Mr. Shantilal Vora as a Non-Executive Non-Independent Director and plans to shift its registered office to Plot No. L-13, L -28, L -28(Pt), L -29 & L -30, MIDC Tarapur, Boisar, Palghar, Maharashtra – 401506. Additionally, Valiant Laboratories approved an investment of up to Rs 60 crore in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited, through the subscription of 1% Optionally Convertible Redeemable Preference Shares.

Valiant Laboratories Limited announced the re-appointment of Mr. Santosh Vora as Managing Director for five years, effective February 6, 2027, and Mrs. Sonal Vira as an Independent Director for a second five-year term, also effective February 16, 2027, both subject to shareholder approval. The company also approved the continuation of Mr. Shantilal Vora as a Non-Executive Non-Independent Director and plans to shift its registered office to Plot No. L-13, L -28, L -28(Pt), L -29 & L -30, MIDC Tarapur, Boisar, Palghar, Maharashtra – 401506, and open a new corporate office in Mumbai. Additionally, Valiant Laboratories intends to invest up to Rs 60 crore in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited, to meet working capital needs.

Valiant Laboratories Limited will hold a board meeting on Monday, August 10, 2026, to consider and approve the Standalone and Consolidated Audited Financial Results for the quarter ended June 30, 2026, according to a regulatory filing. The trading window for the company will remain closed until August 12, 2026, in accordance with SEBI regulations.

Net profit of Valiant Laboratories rose 151.43% to Rs 1.76 crore in the quarter ended March 2026 as against Rs 0.70 crore during the previous quarter ended March 2025. Sales rose 59.16% to Rs 91.98 crore in the quarter ended March 2026 as against Rs 57.79 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 3.27 crore in the year ended March 2026 as against net loss of Rs 2.20 crore during the previous year ended March 2025. Sales rose 78.04% to Rs 237.47 crore in the year ended March 2026 as against Rs 133.38 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales91.9857.79 59 237.47133.38 78 OPM %5.236.61 -2.69-3.50 - PBDT3.971.46 172 6.810.58 1074 PBT1.050.94 12 0.77-1.51 LP NP1.760.70 151 -3.27-2.20 -49 Powered by Capital Market - Live

Valiant Laboratories will hold a meeting of the Board of Directors of the Company on 14 May 2026.

Net loss of Valiant Laboratories reported to Rs 7.06 crore in the quarter ended December 2025 as against net profit of Rs 2.35 crore during the previous quarter ended December 2024. Sales rose 48.91% to Rs 52.46 crore in the quarter ended December 2025 as against Rs 35.23 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales52.4635.23 49 OPM %-1.701.76 - PBDT-0.942.14 PL PBT-2.991.62 PL NP-7.062.35 PL Powered by Capital Market - Live

Valiant Laboratories will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live

Net profit of Valiant Laboratories reported to Rs 0.20 crore in the quarter ended September 2025 as against net loss of Rs 4.74 crore during the previous quarter ended September 2024. Sales rose 115.08% to Rs 46.20 crore in the quarter ended September 2025 as against Rs 21.48 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales46.2021.48 115 OPM %0.15-31.38 - PBDT0.81-3.39 LP PBT0.28-3.91 LP NP0.20-4.74 LP Powered by Capital Market - Live